AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
18.59
-0.28 (-1.48%)
Feb 21, 2025, 4:00 PM EST - Market closed
AnaptysBio Employees
AnaptysBio had 117 employees as of December 31, 2023. The number of employees increased by 21 or 21.88% compared to the previous year.
Employees
117
Change (1Y)
21
Growth (1Y)
21.88%
Revenue / Employee
$488,650
Profits / Employee
-$1,415,880
Market Cap
565.67M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ANAB News
- 10 days ago - Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - GlobeNewsWire
- 10 days ago - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - GlobeNewsWire
- 18 days ago - Anaptys to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 19 days ago - Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist - GlobeNewsWire
- 6 weeks ago - Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data - Benzinga
- 2 months ago - AnaptysBio to abandon eczema drug development after mid-stage trial failure - Reuters
- 2 months ago - AnaptysBio abandons eczema drug development after mid-stage trial failure - Reuters